Evidence map›Paper›PMID 39514050›Full record

ArticleHNO2024

[Highlights of the 2024 ASCO Annual Meeting: radiotherapy of head and neck cancer].

Sören Schnellhardt, Silke Tribius, Maximilian Linxweiler, Antoniu-Oreste Gostian, Markus Hecht

Abstract readConference ProceedingsEnglish Abstract
PubMed Publisher
In one paragraph

Article in HNO, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sören SchnellhardtDepartment of Radiotherapy and Radiation Oncology, Saarland University Medical Center, Homburg, Deutschland.
Silke TribiusHermann-Holthusen-Institute for Radiation Oncology, Asklepios Tumor Zentrum Hamburg, Asklepios Hospital St. Georg, Hamburg, Deutschland.
Maximilian LinxweilerDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, Homburg, Deutschland.
Antoniu-Oreste GostianDepartment of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
Markus HechtDepartment of Radiotherapy and Radiation Oncology, Saarland University Medical Center, Homburg, Deutschland. Radioonkologie@uks.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), several important studies on radiotherapy for head and neck squamous cell carcinoma (HNSCC) were presented. There were two Chinese phase III trials on treatment escalation for locally advanced nasopharyngeal carcinoma: adjuvant immune checkpoint inhibition with camrelizumab after induction chemotherapy and cisplatin-based chemoradiotherapy (RCT) in the DIPPER trial reached the primary endpoint of improved event-free survival (EFS) but did not improve overall survival (OS). Simultaneous and adjuvant administration of the angiogenesis inhibitor endostar in addition to cisplatin-based RCT for locally advanced nasopharyngeal carcinoma led to a significant improvement in progression-free survival (PFS) and OS. Another major focus was on treatment optimization and deintensification for oropharyngeal cancer (OPC): using intensity-modulated proton therapy (IMPT), a phase III trial demonstrated noninferiority in definitive RCT for OPC compared to photon-based intensity-modulated radiotherapy (IMRT). In adjuvant treatment of human papillomavirus-positive (HPV+) OPC, the long-term results of the E3311 phase II study confirmed that individually deintensified radiotherapy is feasible. Lee et al. showed with the results of a phase II study that HPV+ OPC might be treatable with chemoradiotherapy to a total dose of only 30 Gy if no hypoxia is detected in the

Indexed as

Head and Neck NeoplasmsChemoradiotherapyGermanyHumansMedical OncologyTreatment OutcomeHead and neck squamous cell carcinomaHypoxiaImmune checkpoint inhibitionOropharyngeal carcinomaTherapy deescalation

Identifiers

PMID39514050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.